Oramed Pharmaceuticals, Inc

NASDAQ:ORMP   3:59:42 PM EDT
2.50
-0.05 (-1.96%)
Products

Oramed Issues Shareholder Update On Pivotal Phase 3 Oral Insulin Studies Protocols Submitted To FDA

Published: 10/16/2020 13:35 GMT
Oramed Pharmaceuticals Inc (ORMP) - Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA.
Oramed Pharmaceuticals Inc - Submitted to FDA Protocols for Our Upcoming Pivotal Phase 3 Studies for Ormd-0801.
Oramed Pharmaceuticals - Intend to Conduct Two Phase 3 Studies Concurrently in Patients With Type 2 Diabetes.
Oramed Pharmaceuticals Inc - Expect to Conduct a Pre-bla Meeting to Finalize Plans and Data for Bla Submission.